IMDX
Price
$3.20
Change
-$0.17 (-5.04%)
Updated
Jun 27 closing price
Capitalization
24.2M
MLSS
Price
$0.73
Change
-$0.03 (-3.95%)
Updated
Jun 27 closing price
Capitalization
47.46M
51 days until earnings call
Interact to see
Advertisement

IMDX vs MLSS

Header iconIMDX vs MLSS Comparison
Open Charts IMDX vs MLSSBanner chart's image
Insight Molecular Diagnostics
Price$3.20
Change-$0.17 (-5.04%)
Volume$72.08K
Capitalization24.2M
Milestone Scientific
Price$0.73
Change-$0.03 (-3.95%)
Volume$364.21K
Capitalization47.46M
IMDX vs MLSS Comparison Chart in %
Loading...
IMDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MLSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMDX vs. MLSS commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMDX is a Hold and MLSS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (IMDX: $3.20 vs. MLSS: $0.73)
Brand notoriety: IMDX and MLSS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: IMDX: 80% vs. MLSS: 471%
Market capitalization -- IMDX: $24.2M vs. MLSS: $47.46M
IMDX [@Medical Specialties] is valued at $24.2M. MLSS’s [@Medical Specialties] market capitalization is $47.46M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMDX’s FA Score shows that 0 FA rating(s) are green whileMLSS’s FA Score has 0 green FA rating(s).

  • IMDX’s FA Score: 0 green, 5 red.
  • MLSS’s FA Score: 0 green, 5 red.
According to our system of comparison, IMDX is a better buy in the long-term than MLSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMDX’s TA Score shows that 5 TA indicator(s) are bullish while MLSS’s TA Score has 3 bullish TA indicator(s).

  • IMDX’s TA Score: 5 bullish, 4 bearish.
  • MLSS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, IMDX is a better buy in the short-term than MLSS.

Price Growth

IMDX (@Medical Specialties) experienced а -24.53% price change this week, while MLSS (@Medical Specialties) price change was -17.28% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.14%. For the same industry, the average monthly price growth was +1.17%, and the average quarterly price growth was -0.01%.

Reported Earning Dates

MLSS is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Medical Specialties (+1.14% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MLSS($47.5M) has a higher market cap than IMDX($24.2M). IMDX YTD gains are higher at: 34.454 vs. MLSS (-24.271). MLSS has higher annual earnings (EBITDA): -6.99M vs. IMDX (-10.44M). IMDX has more cash in the bank: 14.2M vs. MLSS (4.62M). MLSS has less debt than IMDX: MLSS (422K) vs IMDX (3.07M). MLSS has higher revenues than IMDX: MLSS (9.81M) vs IMDX (1.46M).
IMDXMLSSIMDX / MLSS
Capitalization24.2M47.5M51%
EBITDA-10.44M-6.99M149%
Gain YTD34.454-24.271-142%
P/E Ratio4.56N/A-
Revenue1.46M9.81M15%
Total Cash14.2M4.62M307%
Total Debt3.07M422K728%
FUNDAMENTALS RATINGS
IMDX vs MLSS: Fundamental Ratings
IMDX
MLSS
OUTLOOK RATING
1..100
5152
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4865
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMDX's Valuation (54) in the Medical Specialties industry is somewhat better than the same rating for MLSS (95). This means that IMDX’s stock grew somewhat faster than MLSS’s over the last 12 months.

IMDX's Profit vs Risk Rating (89) in the Medical Specialties industry is in the same range as MLSS (100). This means that IMDX’s stock grew similarly to MLSS’s over the last 12 months.

MLSS's SMR Rating (98) in the Medical Specialties industry is in the same range as IMDX (100). This means that MLSS’s stock grew similarly to IMDX’s over the last 12 months.

IMDX's Price Growth Rating (48) in the Medical Specialties industry is in the same range as MLSS (65). This means that IMDX’s stock grew similarly to MLSS’s over the last 12 months.

IMDX's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as MLSS (100). This means that IMDX’s stock grew similarly to MLSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMDXMLSS
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 19 days ago
90%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IMDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MLSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GROW2.540.06
+2.42%
US Global Investors
V348.612.58
+0.75%
VISA
MDGL299.51N/A
N/A
Madrigal Pharmaceuticals
VERA22.65-0.64
-2.75%
Vera Therapeutics
CURI5.30-0.16
-2.93%
CuriosityStream

IMDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMDX has been loosely correlated with NEPH. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if IMDX jumps, then NEPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMDX
1D Price
Change %
IMDX100%
-5.04%
NEPH - IMDX
36%
Loosely correlated
-8.96%
FONR - IMDX
31%
Poorly correlated
+3.19%
MASS - IMDX
24%
Poorly correlated
-0.15%
MLSS - IMDX
24%
Poorly correlated
-4.34%
LUCY - IMDX
22%
Poorly correlated
-2.80%
More

MLSS and

Correlation & Price change

A.I.dvisor tells us that MLSS and BLFS have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MLSS and BLFS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLSS
1D Price
Change %
MLSS100%
-4.34%
BLFS - MLSS
29%
Poorly correlated
+0.56%
ANGO - MLSS
26%
Poorly correlated
-0.91%
PRE - MLSS
26%
Poorly correlated
-5.67%
ESTA - MLSS
25%
Poorly correlated
+0.22%
HBIO - MLSS
25%
Poorly correlated
-9.44%
More